Chlorpromazine combined with cidofovir for treatment of a patient suffering from progressive multifocal leukoencephalopathy

Intervirology

Volumn 50, Issue 6, 2008, Pages 412-417

  Pöhlmann, Christoph ^a   Hochauf, Kristina ^a   Röllig, Christoph ^a   Schetelig, Johannes ^a   Wunderlich, Olaf ^a   Bandt, Dirk ^a   Ehninger, Gerhard ^a   Jacobs, Enno ^a   Rohayem, Jacques ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Institut für Virologie   (Germany)

Author keywords

Chlorpromazine; Cidofovir; JC viral load; Progressive multifocal leukoencephalopathy

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CHLORPROMAZINE; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN; PREDNISOLONE; PREDNISONE; PROBENECID; TACROLIMUS; VALGANCICLOVIR; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; B CELL LEUKEMIA; BLINDNESS; CASE REPORT; CAUSE OF DEATH; CEREBROSPINAL FLUID ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEMENTIA; DEMYELINATING DISEASE; DEMYELINATION; DISEASE COURSE; DISEASE SEVERITY; DISORIENTATION; DROWSINESS; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FECES INCONTINENCE; FOLLOW UP; GAIT DISORDER; GRAFT VERSUS HOST REACTION; HEARING IMPAIRMENT; HLA MATCHING; HOMONYMOUS HEMIANOPIA; HUMAN; IMMUNOPROPHYLAXIS; JC VIRUS; LEUKEMIA REMISSION; MALE; MENTAL INSTABILITY; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PATIENT REFERRAL; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REDUCED INTENSITY CONDITIONING; SKIN DEFECT; TREATMENT DURATION; TREMOR; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; VERTIGO; VIRUS DETECTION; VIRUS GENOME; VIRUS REACTIVATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; BRAIN; CHLORPROMAZINE; CYTOSINE; DNA, VIRAL; DRUG THERAPY, COMBINATION; FATAL OUTCOME; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PHOSPHONIC ACIDS;

JC POLYOMAVIRUS;

EID: 39749191853     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112916     Document Type: Article

References (34)

1. Ryschkewitsch C, Jensen P, Hou J, Fahle G, Fischer S, Major EO: Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 2004;121:217-221.
2. Watzinger F, Suda M, Preuner S, Baumgartinger R, Ebner K, Baskova L, Niesters HG, Lawitschka A, Lion T: Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients. J Clin Microbiol 2004;42:5189-198.
3. Berger JR, Levy RM, Flomenhoft D, Dobbs M: Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998;44:341-349.
4. Reiss K, Khalili K: Viruses and cancer: lessons from the human polyomavirus, JCV. Oncogene 2003;22:6517-6523.
5. Andrei G, Snoeck R, Vandeputte M, De Clercq E: Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997;41:587-593.
6. De Clercq E: Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, poxand adenovirus) infections. Verh K Acad Geneeskd Belg 1996;58:19-47;discussion 47-49.
7. Hou J, Major EO: The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 1998;4:451-456.
8. Viallard JF, Lazaro E, Lafon ME, Pellegrin JL: Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T237 cell lymphoma. Leuk Lymphoma 2005;46:1659-1662.
9. Cid J, Revilla M, Cervera A, Cervantes F, Munoz E, Ferrer I, Montserrat E: Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol 2000;79:392-395.
10. Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, Roth BL, Atwood WJ: The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004;306:1380-1383.
11. Pho MT, Ashok A, Atwood WJ: JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J Virol 2000;74:2288-2292.
12. Altschuler EL, Kast RE: The atypical antipsychotic agents ziprasidone, risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses 2005;65:585-586.
13. Koralnik IJ, Du Pasquier RA, Kuroda MJ, Schmitz JE, Dang X, Zheng Y, Lifton M, Letvin NL: Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 2002;168:499-504.
14. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ: A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004;127:1970-1978.
15. Gasnault J, Kahraman M, de Goer de Herve MG, Durali D, Delfraissy JF, Taoufik Y: Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 2003;17:1443-1449.
16. Singh N: Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Curr Opin Infect Dis 2005;18:342-345.
17. Hirsch HH: Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant 2002;2:25-30.
18. Ettinger J, Feiden W, Hubner G, Schreiner M: Progressive multifocal leukoencephalopathy in Wegener's granulomatosis in relation to therapy with cyclosporin A (in German). Klin Wochenschr 1989;67:260-264.
19. Gentile S, Sacerdote I, Roccatello D, Giordana MT: Progressive multifocal leukoencephalopathy during cyclosporine treatment: a case report. Ital J Neurol Sci 1996;17:363-366.
20. Newton P, Aldridge RD, Lessells AM, Best PV: Progressive multifocal leukoencephalopathy complicating systemic lupus erythematosus. Arthritis Rheum 1986;29:337-343.
21. Itoh K, Kano T, Nagashio C, Mimori A, Kinoshita M, Sumiya M: Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:1020-1022.
22. Sponzilli EE, Smith JK, Malamud N, McCulloch JR: Progressive multifocal leukoencephalopathy: a complication of immunosuppressive treatment. Neurology 1975;25:664-668.
23. Morgenstern LB, Pardo CA:Progressive multifocal leukoencephalopathy complicating treatment for Wegener's granulomatosis. J Rheumatol 1995;22:1593-1595.
24. Warnatz K, Peter HH, Schumacher M, Wiese L, Prasse A, Petschner F, Vaith P, Volk B, Weiner SM: Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis 2003;62:50-57.
25. Wang M, Tsai RT, Ou WC, Lin CK, Tsay GJ, Chang H, Chang D: Treatment with cytotoxic immunosuppression agents increases urinary excretion of JCV in patients with autoimmune disease. J Med Virol 2000;62:505-510.
26. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ: Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998;129:559-566.
27. Kiewe P, Seyfert S, Korper S, Rieger K, Thiel E, Knauf W: Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma 2003;44:1815-18.
28. Saumoy M, Castells G, Escoda L, Mares R, Richart C, Ugarriza A: Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma 2002;43:433-436.
29. Vidarsson B, Mosher DF, Salamat MS, Isaksson HJ, Onundarson PT: Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am J Hematol 2002;70:51-54.
30. Knechtle SJ, Pirsch JD, H. Fechner JJ, Becker BN, Friedl A, Colvin RB, Lebeck LK, Chin LT, Becker YT, Odorico JS, D'Alessandro AM, Kalayoglu M, Hamawy MM, Hu H, Bloom DD, Sollinger HW: Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003;3:722-730.
31. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-3561.
32. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santabarbara P, Wacker B, Brettman L: Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-3897.
33. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, Mollgard L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B322 CLL). Blood 2002;100:768-773.
34. Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, Shutt KA, Shapiro R, Thai N, Abu-Elmagd K, McCurry KR, Marcos A, Paterson DL: Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007;44:204-212.